The US Food and Drug Administration (FDA) has approved efgartigimod (Vyvgart, argenx), a first-in-class, targeted therapy for adults with generalized myasthenia gravis (gMG) who test positive for the antiacetylcholine receptor (AChR) antibody... Full text at: https://www.medscape.com/viewarticle/965109
This was in the national news because the drug was developed by a Belgian company. It is based on antibodies of lama's and the company hopes to test it out on other illnesses as well. The phase III study for myasthenia gracvs was published in Lancet Neurology: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00159-9/fulltext
